$Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort$

Panobinostat in combination with bortezomib and dexamethasone in multiply relapsed and refractory myeloma; UK routine care cohort

The combination of panobinostat, bortezomib and dexamethasone (PanBorDex) is available as a treatment option for relapsed refractory multiple myeloma (RRMM) based on the PANORAMA-1 trial which investigated this triplet in early relapse. In routine clinical care, PanBorDex is used primarily in later...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PloS one 2022-07, Vol.17 (7), p.e0270854-e0270854
Hauptverfasser:	Maouche, Nadjoua, Kishore, Bhuvan, Bhatti, Zara, Basu, Supratik, Karim, Farheen, Sundararaman, Sharadha, Collings, Freya, Tseu, Bing, Leary, Heather, Ryman, Noel, Reddy, Udaya, Vallance, Grant D., Kothari, Jaimal, Ramasamy, Karthik
Format:	Artikel
Sprache:	eng
Schlagworte:	Biology and Life Sciences Bortezomib Care and treatment Complications and side effects Criteria Dexamethasone Diarrhea Dosage Health risk assessment Health services Inhibitor drugs Medicine and Health Sciences Multiple myeloma Patient outcomes Patients Research and Analysis Methods Response rates Schedules Steroids Survival Targeted cancer therapy Thrombocytopenia Toxic diseases Toxicity
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!